Company / Net Income
Avalo Therapeutics, Inc. Net Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$78.3M
FY2025
5-year range
-$84.4M / -$31.5M
FY2021-FY2025
Trend
-122.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 9 years, ranging from -$84M in FY2021 to $12M in FY2017.
Based on SEC 10-K filings.
-$78M in FY2025.
Declined from -$32M to -$78M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 122.8% year-over-year.
- Peak net income was recorded in FY2017.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$78.3M | -122.8% |
| FY2024 | -$35.1M | -11.4% |
| FY2023 | -$31.5M | +24.3% |
| FY2022 | -$41.7M | +50.6% |
| FY2021 | -$84.4M | -32.9% |
| FY2020 | -$63.5M | -295.1% |
| FY2019 | -$16.1M | +59.9% |
| FY2018 | -$40.1M | -437.4% |
| FY2017 | $11.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026